Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours
10 Apr 2017
Results of SUMMIT: a global phII trial of neratinib in HER2/3 mutant solid tumours
Neratinib in HER2 or HER3 mutant solid tumours
75 years of Tata Memorial Centre
Translational research and treating resistance
Mechanisms of resistance in triple negative breast cancer
Personalising breast cancer therapies
Editor's Choice for March 2017
Sampling brain tumours for personalised treatment
Novel treatment approaches in Ph like ALL
Advances in paediatric ALL
Cimavax - a lung cancer vaccine
Promising partners for check-point immunotherapy for HCC?